GSA Capital Partners LLP Sells 411,331 Shares of Ironwood Pharmaceuticals, Inc. $IRWD

GSA Capital Partners LLP trimmed its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 57.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 309,529 shares of the biotechnology company’s stock after selling 411,331 shares during the period. GSA Capital Partners LLP’s holdings in Ironwood Pharmaceuticals were worth $405,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of IRWD. Merit Financial Group LLC boosted its position in Ironwood Pharmaceuticals by 17.4% during the third quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 7,232 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Ironwood Pharmaceuticals by 3.5% during the 3rd quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 7,611 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 43.5% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 72,706 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 22,029 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 23.1% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 154,388 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 28,928 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC grew its stake in shares of Ironwood Pharmaceuticals by 284.6% in the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 29,409 shares in the last quarter.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $3.36 on Thursday. Ironwood Pharmaceuticals, Inc. has a 52 week low of $0.53 and a 52 week high of $5.78. The company has a market capitalization of $546.60 million, a price-to-earnings ratio of 21.00 and a beta of 0.17. The company has a 50-day simple moving average of $4.27 and a 200 day simple moving average of $2.80.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%.The company had revenue of $47.71 million for the quarter, compared to analyst estimates of $86.10 million. Sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on IRWD shares. Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Citigroup raised shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Wells Fargo & Company boosted their price target on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. Finally, Citizens Jmp upgraded Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 price objective on the stock in a research note on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $3.68.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.